+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Subcutaneous Immunoglobulin Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 4986957
  • Report
  • February 2020
  • Region: Global
  • 120 pages
  • Mordor Intelligence
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Bio Products laboratory
  • Biotest AG
  • CSL Behring
  • Grifols, S.A.
  • Kedrion S.p.A.
  • Octapharma AG
  • MORE
The subcutaneous immunoglobulin market studied was projected to grow with a CAGR of nearly 13.3% over the forecast period. The major factors attributing to the growth of the market include increasing use of subcutaneous immunoglobulin for primary immunodefeciency disorders, increasing geriatric population and patient pool. The growing demand of the subcutaneous immunoglobulin infusions are due to the advantages like absence of necessity of vascular access, easy use at home, more stable serum IgG levels and efficient prevention against infections. Furthermore the growing investements in research and development programs by the biotechnology and pharmaceutical companiesis boosting the market growth. Rising government fundings and increasing awareness about usage of subcutaneous immunoglobulin for treatment of immunodefeciency disorders boosts the market growth. However the stringent government regulations and high risk of the side effects of the treatment are the major drawbacks for the market growth.

Key Market Trends

Primary Immunodeficiency Diseases Segment to Dominate the Market in the Forecast Period
  • Primary immunodeficiency diseases have the largest market share and are expected to do the same in the forecast period. The dominance of the segment can be credited to the soaring prevalence of primary immunodeficiency diseases, growing usage and awareness of subcutaneous immunoglobulin, rising research and development activities in the field of plasma-derived therapeutics.
  • According to the Immune Deficiency Foundation, there are approximately 250,000 people who have been diagnosed with primary immunodeficiency diseases in the United States. The rate of incidence of the severe combined immunodeficiency disease was 1 in 10,000 in 2008 and it has changed to 1 in 4000, in 2018. The prevalence of primary immunodeficiency diseases is rising and hence the market growth.
North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall subcutaneous immunoglobulin market, throughout the forecast period. The market growth is due to the factors such as the presence of key players, high prevalence of primary immunodeficiency diseases patients and increasing geriatric population in the region, established healthcare infrastructure, are some of the key factors accountable for its large share in the market. Furthermore, beneficial government initiatives and an increase in the number of research partnerships are some of the drivers expected to increase market growth.

Competitive Landscape

The subcutaneous immunoglobulin market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are Takeda Pharmaceutical Company Limited, Biotest AG, CSL Behring, Grifols, S.A., Octapharma AG, Kedrion S.p.A., Bio Products laboratory.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • Report customization as per the client's requirements.
  • 3 months of analyst support.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Bio Products laboratory
  • Biotest AG
  • CSL Behring
  • Grifols, S.A.
  • Kedrion S.p.A.
  • Octapharma AG
  • MORE
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing use of subcutaneous immunoglobulin for primary immunodefeciency disorders
4.2.2 Increasing geriatric population and patient pool
4.2.3 Rise in government funding
4.3 Market Restraints
4.3.1 Stringent government regulations
4.3.2 High risk of side effects
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

5.1 By Application
5.1.1 Primary Immunodeficiency Diseases
5.1.2 Secondary Immunodeficiency Diseases
5.1.3 Others
5.2 By End-User
5.2.1 Hospitals
5.2.2 Homecare Settings
5.2.3 Others
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

6.1 Company Profiles
6.1.1 Takeda Pharmaceutical Company Limited
6.1.2 Biotest AG
6.1.3 CSL Behring
6.1.4 Grifols, S.A.
6.1.5 Octapharma AG
6.1.6 Kedrion S.p.A.
6.1.7 Bio Products laboratory

7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Takeda Pharmaceutical Company Limited
  • Biotest AG
  • CSL Behring
  • Grifols, S.A.
  • Octapharma AG
  • Kedrion S.p.A.
  • Bio Products laboratory
Note: Product cover images may vary from those shown
Adroll
adroll